CT-TIL-001

CT-TIL-001 is an autologous tumor-infiltrating lymphocyte (TIL) therapy developed by CAR-T (Shanghai) Cell Biotechnology Co., Ltd. for the treatment of hepatocellular carcinoma (HCC) and other solid tumors. The therapeutic process involves the isolation of naturally occurring T cells from a patient's own tumor tissue, followed by ex vivo expansion in the presence of interleukin-2 (IL-2) to generate a large population of tumor-reactive cells, typically reaching 10^9 to 10^10 cells. These expanded TILs, which possess a diverse repertoire of endogenous T-cell receptors (TCRs) capable of recognizing multiple tumor-specific antigens, are then re-infused into the patient. CT-TIL-001 is specifically being evaluated in clinical trials for patients with high-risk recurrent primary hepatocellular carcinoma following radical resection to prevent or treat recurrence by leveraging the patient's own immune system to target residual cancer cells.

Other names

Tumor infiltrating lymphocyteAutologous tumor-infiltrating lymphocytesAutologous TILsTILsH-TIL